Antiviral treatments spending: -32%
Antiviral treatments usage: +7%
Antibacterial treatments spending: -3%
Antibacterial treatments usage: -1%
Pre-exposure prophylaxis for HIV (PrEP)
New Zealand became one of the first countries in the world to fund pre-exposure prophylaxis (or PrEP) treatment for HIV (human immunodeficiency virus).
PHARMAC took this step in helping control the spread of HIV by widening access to Truvada as a preventive medicine for high risk individuals.
Widening funded access to Truvada will benefit up to 4000 people each year. After years of declining HIV infection rates, that trend has recently reversed and is now increasing. We expect that funding PrEP will significantly reduce HIV transmission rates in New Zealand.
PHARMAC started funding new treatments for Hepatitis C in 2016 which give people the chance of a hepatitis C cure in as little as 12 weeks of treatment. Over 1100 more people have been treated over the last year, bringing the total number treated to over 2300 people.
An estimated 50% of people who have hepatitis C don’t know they have it. We are continuing to work with the health sector to find ways to identify and treat even more people in general practice and primary care.
We are also working towards funding a pangenotypic treatment so that all people with chronic hepatitis C can access a funded treatment, regardless of disease genotype.
Responsible use of antibiotics
Along with providing new antimicrobial treatments, we are also responsible for ensuring the ones we already fund are used responsibly.
We ran a “Keep antibiotics working” campaign this year, to coincide with the traditional months of the winter flu season.
Overusing antibiotics, especially when they’re not needed, is contributing to antibiotic resistance. This is a global health threat, and we all need to help keep antibiotics working. We can help reduce antibiotic resistance by only using antibiotics when they are needed.
|Financial year||Amoxycillin||Amoxycillin clavulanate|
Last updated: 13 December 2018